Overactive Bladder Treatment Market

Market Overview

The global overactive bladder treatment market size was valued at USD 4.1 billion in 2022. It is projected to reach USD 5.73 billion by 2031, growing at a CAGR of 3.8% during the forecast period (2023–2031).

The condition known as overactive bladder (OAB) results in frequent, unexpected urinal urges that can be challenging to control. An overactive bladder develops when the muscles start to contract violently, even when there isn't much urine in the bladder. These involuntary contractions bring on the sudden urge to urinate. One may experience frequent urges to urinate both during the day and at night and unintentional urine loss (urgency incontinence). Bladder contracts giving little time or no time to reach the toilet. This condition is also known as urge incontinence. The increasing aging population, increase in diabetic population, continuous rise in prevalence of overactive bladder conditions, increasing consumption of alcohol and caffeinated drinks, and neurological conditions such as multiple sclerosis and Parkinson’s contribute significantly to the market growth.

Urge to urinate suddenly and find it difficult to control; unintentional loss of urine after an urgent need to urinate; frequent urination, typically eight or more times per day; and waking up more than twice during the night to urinate are some symptoms (nocturia). As per Urology Care Foundation, around 33 million Americans have overactive bladder, in which 30% of men and 40% of women live with OAB symptoms. In addition, National Overactive Bladder Evaluation (NOBLE) program conducted a telephone survey and found that 16.9% of women had OAB, 9.3% with urge incontinence, and 7.6% without urge incontinence.  It also revealed that 16% of men had OAB in Canada.

Market Dynamics

Global Overactive Bladder Treatment Market Drivers

Rising R&D Spending and the Introduction of New Treatments in the Upcoming Years

Pharmaceutical and biopharmaceutical companies are investing in cutting-edge therapies to treat overactive bladders, which are anticipated to be introduced during the forecast period. For instance, TAC-302, a drug currently in Phase II development, is being developed by Taiho Pharmaceutical. This medication is orally bioavailable and promotes neurite outgrowth activity in cultured peripheral neurons to treat overactive bladder. The introduction of innovative treatment options will boost patient uptake, which will fuel market expansion. The overactive bladder treatment also gives you a detailed analysis of each country's growth in healthcare spending on capital equipment, the installed base of various overactive bladder treatment market products, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their effects on the market.

New Technologies will aid the Development of The Overactive Bladder Market.

An overactive bladder (OAB) clinical condition occurs when the bladder muscle contracts unintentionally. Urinary urgency, urgency incontinence, frequent urination, and nocturia are symptoms. Some other medical conditions can also cause an overactive bladder. The initial course of treatment for OAB includes behavior modification, bladder training, and pelvic floor exercises. A medication trial is the second line of treatment. The next-generation implant, sacral neuromodulation for OAB, is more user-friendly, lasts longer, and has fewer contraindications. Increased product launches to support the market During the forecast period; increased product launches are anticipated to support industry growth. For example, the FDA-approved cefiderocol (FETROJA) for treating complicated urinary tract infections (CUTI), including pyelonephritis, caused by Gram-negative microorganisms like Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex in patients of age18 or older with limited.

Global Overactive Bladder Treatment Market Restraint

Frequently Recalling Products

A chronic medical condition that lowers the quality of life, overactive bladder affects a sizable portion of the population. The market growth could be hampered by frequent recalls of OAB-treating medications in the coming years. Due to production problems, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US. The market for treating overactive bladder is experiencing slow growth due to these frequent recalls by top pharmaceutical companies. Many other companies, such as Lannett Company Inc., recalled more than 14000 bottles containing 100 tablets. The recalled bottles were sold all over the country, including Puerto Rico. The FDA has classified the recalls as Class III, indicating that using the recalled tablets is unlikely to hurt one's health.

Global Overactive Bladder Treatment Market Opportunities

Novel Therapies, Strong Pipelines, And the Approaching Patent Cliff for Some Drugs

More than 30 OAB candidates are presently in clinical trial pipelines. These are divided into three Phase II, seven Phase III, and sixteen Phase IV projects. The market for treating overactive bladder is anticipated to grow due to this strong pipeline and the subsequent introduction of newer medications and therapies. Samsung Medical Center is researching potential biomarkers in OAB patients, including adenosine triphosphate (ATP), prostaglandin E2 (PGE2), and nerve growth factor (NGF). This will help predict how well a treatment will work to deliver customized care. Players in the OAB treatment market can expect to benefit from significant growth opportunities due to such developments.

Regional Analysis

The global overactive bladder treatment market is divided into four regions: North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant shareholder in the global overactive bladder treatment market and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S. and Canada are included in the analysis of the overactive bladder treatment market in North America. The area’s dominance is attributed to several factors, including favorable reimbursement policies for treatment options and an increase in the number of patients with overactive bladder in the US. Additionally, the region's market is expanding due to consumer preference among businesses operating there and ANDA and FDA approval for various treatments. The market in North America is expanding due to the rising incidence of neurological diseases and the rising prevalence of overactive bladder in the elderly population. Favorable reimbursement scenarios for the treatment of overactive bladder and increased research activities are additional factors driving the growth of the North American market. According to the Cleveland Clinic Organization, overactive bladder affects 33 million adults in the US.

Asia Pacific is expected to grow fastest at a CAGR of 4.1% during the forecast period. China, India, Japan, Australia, and the rest of Asia-Pacific are all included in the analysis of the Asia-Pacific overactive bladder treatment market. The overactive bladder market is expected to witness significant growth due to an increase in the geriatric population and a rise in awareness among people regarding the condition. As per The Journal of Obstetrics and Gynecology of India, around 1 in 3 women over 75 years of age and 1 in 15 women over 40 years suffer from the symptoms of an overactive bladder.

Segmental Analysis

The market is segmented by pharmacotherapy and disease type.

Based on pharmacotherapy, the global overactive bladder treatment market is bifurcated into anticholinergics, Botox, intravesical instillation, mirabegron, and neurostimulation. Anticholinergics are sub-segmented into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and other anticholinergics.

The Anticholinergics segment is the highest contributor to the market and is expected to grow at a CAGR of 3.9% during the forecast period. One of the first lines of medical treatment for an overactive bladder is anticholinergic medication (OAB). Anticholinergic medications help to counteract the effects of the neurotransmitter acetylcholine and treat a variety of conditions linked to the activation of the parasympathetic nervous system, which reduces bladder muscle spasms. Acetylcholine (ACh), a neurotransmitter, acts at synapses in the central and peripheral nervous systems. Anticholinergics (anticholinergic agents) are substances that block this action. A toxic reaction known as the acute anticholinergic syndrome may happen when the body ingests a significant amount of anticholinergic. Although many users find the side effects incredibly unpleasant and not worth the recreational effects they experience, this may occur accidentally or on purpose as a result of either recreational or entheogenic drug use. Anticholinergics are frequently referred to as deliriants in the context of recreational use.

Based on disease type, the global overactive bladder treatment market is bifurcated into the idiopathic overactive bladder and neurogenic overactive bladder. Neurogenic overactive bladder is further segmented into the overactive bladder in Parkinson’s disease, overactive bladder in stroke, overactive bladder in multiple sclerosis, and overactive bladder in spinal cord injury.

The idiopathic overactive bladder segment is the highest contributor to the market and is expected to grow at a CAGR of 3.6% during the forecast period. Idiopathic overactive bladder (OAB) is a chronic syndrome that describes frequent nighttime urination, urinary urgency, and other symptoms that hurt a person's life. The idiopathic overactive bladder syndrome market share was higher due to the higher prevalence of idiopathic overactive bladder disorders. Additionally, it is anticipated that increased use of SNM therapy for patients with idiopathic overactive bladder will aid in segmental growth. Idiopathic OAB, which includes conditions like urinary tract infection, bladder cancer, bladder stones, bladder inflammation, and bladder outlet obstruction, is OAB that does not have any known underlying neurologic, metabolic, or other causes. OAB symptoms may result from some medications.

Recent Developments

• September 2022, First Patient Implants with New Recharge-Free Sacral Neuromodulation System Announced by Axonics in Canada. Following U.S. FDA approval, the Axonics F15 received regulatory approval from Health Canada.
• February 2022, AbbVie reported that the US Food and Drug Administration (FDA) had authorized BOTOX to treat detrusor (bladder muscle) overactivity related to a neurologic condition in pediatric patients aged five and older who have an insufficient response to or are intolerable of anticholinergic medication.